Canagliflozin monotherapy: Clinical study data in type 2 diabetes mellitus;Canagliflozin in der Monotherapie: Klinische Studiendaten bei Diabetes mellitus Typ 2

Deutsche Medizinische Wochenschrift

Volumn 139, Issue SUPPL 1, 2014, Pages

  Matthaei, S ^a  

^a Diabetes Zentrum Quakenbruck   (Germany)

Author keywords

blood pressure; canagliflozin; glycaemic control; monotherapy; SGLT 2 inhibition; type 2 diabetes

Indexed keywords

CANAGLIFLOZIN;

MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; CLINICAL STUDY;

BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CLINICAL TRIALS, PHASE III AS TOPIC; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SODIUM-GLUCOSE TRANSPORTER 2; THIOPHENES;

EID: 84893454325     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0033-1359992     Document Type: Review

References (19)

1. Basile J. N. The potential of sodium glucose cotransporter 2 (SGLT2) inhibitors to reduce cardiovascular risk in patients with type 2 diabetes (T2DM). J Diabetes Complications: 2013; 27 280 286
2. Chan H. W., Ashan B., Jayasekera P. et al. A new class of drug for the management of type 2 diabetes: sodium glucose co-transporter inhibitors: 'glucuretics'. Diabetes Metab Syndr: 2012; 6 224 228
3. Chen L. H., Leung P. S. Inhibition of the sodium glucose co-transporter-2: its beneficial action and potential combination therapy for type 2 diabetes mellitus. Diabetes Obes Metab: 2013; 15 392 402
4. Deshmukh A. B., Patel M. C., Mishra B. SGLT2 Inhibition: A Novel Prospective Strategy in Treatment of Diabetes Mellitus. Ren Fail: 2013; 35 566 572
5. Ferrannini E., Cushman W. C. Diabetes and hypertension: The bad companions. Lancet: 2012; 380 601 610
6. Foote C., Perkovic V., Neal B. Effects of SGLT2 inhibitors on cardiovascular outcomes. Diab Vasc Dis Res: 2012; 9 117 123
7. Inzucchi S. E., Bergenstal R. M., Buse J. B. et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care: 2012; 35 1364 1379
8. Kassenärztliche Vereinigung Nordrhein (KVNO) Qualitä tssicherungsbericht 2009: Disease-Management-Programme in Nordrhein. DMP Diabetes mellitus Typ 2. http://www.kvno.de/downloads/quali/qualbe-dmp09.pdf (letzter Zugriff 11.12.2013)
9. Komala M. G., Panchapakesan U., Pollock C. et al. Sodium glucose cotransporter 2 and the diabetic kidney. Curr Opin Nephrol Hypertens: 2013; 22 113 119
10. Lamos E. M., Younk L. M., Davis S. N. Canagliflozin, an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus. Expert Opin Drug Metab Toxicol: 2013; 9 763 775
11. Mancia G., Fagard R., Narkiewicz K. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J: 2013; 34 2159 2219
12. Patel A., MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet: 2007; 370 829 840 (Pubitemid 47362321)
13. Polidori D., Sha S., Mudaliar S. et al. Canagliflozin Lowers Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption in Addition to Increasing Urinary Glucose Excretion: Results of a randomized, placebo-controlled study. Diabetes Care: 2013; 36 2154 2161
14. Raskin P. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus. Diabetes Metab Res Rev: 2013; 29 347 356
15. Sha S., Devineni D., Ghosh A. et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects. Diabetes Obes Metab: 2011; 13 669 672
16. Stenlöf K., Cefalu W. T., Kim K. A. et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab: 2013; 15 372 382
17. UK Prospective Diabetes Study Group Tight Blood Pressure Control and Risk of Macrovascular and Microvascular Complications in Type 2 Diabetes: UKPDS 38. BMJ: 1998; 317 703 713
18. Vijan S., Hayward R. A. Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care. Ann Intern Med: 2003; 138 593 602
19. Wilke T., Ahrendt P., Schwartz D. et al. Inzidenz und Prävalenz von Diabetes mellitus Typ 2 in Deutschland. Eine Analyse auf Basis von 5,43 Mio. Patientendaten. Dtsch Med Wochenschr: 2013; 1380 69 75